Salvia BioElectronics

Executive Summary

Salvia BioElectronics is a pioneering medical device company based in Eindhoven, Netherlands, dedicated to transforming the lives of migraine sufferers. Founded in 2017, the company develops neuromodulation devices designed to provide non-invasive, drug-free relief for acute and chronic migraine. Migraine affects over a billion people worldwide, yet existing treatments often fall short due to side effects or limited efficacy. Salvia's approach leverages advanced bioelectronics to modulate neural pathways implicated in migraine attacks, offering a potential paradigm shift in management. The company is currently in Phase 1 clinical trials, evaluating the safety and preliminary efficacy of its lead device in patients. Early momentum includes a strong intellectual property portfolio and a management team with deep expertise in neurostimulation and medical device commercialization. As Salvia progresses through clinical development, it aims to address a significant unmet need with a scalable, patient-friendly solution. The company's strategy focuses on generating robust clinical evidence to support regulatory approvals in the EU and US. With the global neuromodulation market projected to grow rapidly, Salvia is well-positioned to capture a share if its device demonstrates favorable outcomes. Key upcoming milestones include completion of the Phase 1 study, which will inform design of pivotal trials. If successful, the company could become a leader in bioelectronic migraine therapy, offering a novel alternative to pharmacological treatments and improving quality of life for millions.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Clinical Trial Results70% success
• Q2 2027Regulatory Submission for CE Mark50% success
• Q1 2027Series B Financing Round80% success